NCT07169825

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

Detailed description

Primary Objectives • To determine the personalized radiation dose to tumors and critical organs of participants with compromised renal and / or bone marrow function. Secondary Objectives * To compare target radiation doses based on varying SPECT scan duration. Plot the variability in target radiation dose versus scan duration. * To compare the image quality and dosimetry results when considering the low, high, and both energy peaks of Lu-177. * To compare target radiation doses based on multiple imaging time points versus a single time point and identify which time point is most suited for this evaluation. * To compare target radiation doses derived from organ versus voxel dosimetry calculation.

Conditions

• Lu-177 PSMA

Interventions

Type	Name	Description
DRUG	Lu-177	Given by IV
OTHER	SPECT	SPECT/CT

Timeline

• Start date: 2026-03-30
• Primary completion: 2026-09-01
• Completion: 2028-09-01
• First posted: 2025-09-12
• Last updated: 2026-04-02

Locations

1 site across 1 country: United States